NCT00437658 - Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis | Biotech Hunter

Enrollment

252

Participants

Timeline

Start Date

December 11, 2006

Primary Completion Date

November 24, 2008

Study Completion Date

November 24, 2008

Conditions

Endometriosis

Interventions

DRUG

Elagolix

Provided as tablets for oral administration

DRUG

Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)

Provided for subcutaneous injection in a prefilled syringe, 104 mg/0.65 mL per syringe.

DRUG

Placebo to Elagolix

Matching placebo tablets for oral administration

DRUG

Placebo to DMPA-SC

Matching placebo for subcutaneous injection in a pre-filled syringe